Empagliflozin as treatment in glycogen storage disease type IB patients
Background: Glycogen Storage Disease Ib (GSD Ib) is a disease that associates both neutropenia and neutrophil dysfunction, thereby causing recurrent infections and inflammatory bowel disease (IBD). As of now, the standard treatment of these complications has been the administration of granulocyte-st...
Saved in:
| Main Authors: | María Arbelo Rodríguez, Elena Márquez Mesa, Cristina Lorenzo González, Marina Gutiérrez Vilar, Loredana Arhip, Mónica Ruiz Pons, José Pablo Suárez Llanos |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Molecular Genetics and Metabolism Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214426925000412 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glycogen storage disease type Ib: modern understanding of the pathogenesis of neutropenia and prospects for its treatment with empagliflozin
by: Andrej N. Surkov, et al.
Published: (2023-11-01) -
Glycogen Storage Disease Type Ib: The First Case in Taiwan
by: Hui-Ju Hsiao, et al.
Published: (2009-06-01) -
Molecular characterization of autosomal recessive Glycogen storage disease type Ib in a Pakistani family
by: Zeeshan Nazir, et al.
Published: (2025-03-01) -
Glycogen Storage Disease Type Ib in the Compound Heterozygous State: Case Report
by: Nikol P. Shimkova, et al.
Published: (2025-05-01) -
Sodium-Dependent Glucose Transporter Type 2 Inhibitors as a Breakthrough in Neutropenia and Neutrophil Dysfunction Management in Patients with Glycogen Storage Disease Type Ib
by: Andrey N. Surkov, et al.
Published: (2024-07-01)